• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有茚满支架的高亲和力刚性化AT受体配体。

High affinity rigidified AT receptor ligands with indane scaffolds.

作者信息

Wallinder Charlotta, Sköld Christian, Sundholm Sara, Guimond Marie-Odile, Yahiaoui Samir, Lindeberg Gunnar, Gallo-Payet Nicole, Hallberg Mathias, Alterman Mathias

机构信息

Department of Medicinal Chemistry , BMC , Uppsala University , P.O. Box 574 , SE-751 23 Uppsala , Sweden.

Service of Endocrinology , Faculty of Medicine and Health Sciences , University of Sherbrooke , Sherbrooke , J1H 5N4 Quebec , Canada.

出版信息

Medchemcomm. 2019 Nov 18;10(12):2146-2160. doi: 10.1039/c9md00402e. eCollection 2019 Dec 1.

DOI:10.1039/c9md00402e
PMID:32904210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7451071/
Abstract

Rigidification of the isobutyl side chain of drug-like AT receptor agonists and antagonists that are structurally related to the first reported selective AT receptor agonist 1 (C21) delivered bioactive indane derivatives. Four enantiomer pairs were synthesized and the enantiomers were isolated in an optical purity >99%. The enantiomers , , , , , , and bind to the AT receptor with moderate ( = 54-223 nM) to high affinity ( = 2.2-7.0 nM). The enantiomer with positive optical rotation (+) exhibited the highest affinity at the receptor. The indane derivatives and are among the most potent AT receptor antagonists reported so far. As illustrated by the enantiomer pairs / and /, an alteration at the stereogenic center has a pronounced impact on the activation process of the AT receptor, and can convert agonists to antagonists and .

摘要

与首个报道的选择性AT受体激动剂1(C21)结构相关的类药物AT受体激动剂和拮抗剂的异丁基侧链刚性化产生了生物活性茚满衍生物。合成了四对对映体,并以>99%的光学纯度分离出对映体。对映体 、 、 、 、 、 、 和 以中等亲和力( = 54 - 223 nM)至高亲和力( = 2.2 - 7.0 nM)与AT受体结合。具有正旋光性(+)的对映体在受体上表现出最高亲和力。茚满衍生物 和 是迄今为止报道的最有效的AT受体拮抗剂。如对映体对 / 和 / 所示,手性中心的改变对AT受体的激活过程有显著影响,并且可以将激动剂转化为拮抗剂 。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/72a6168a15dd/c9md00402e-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/b9c96f038c96/c9md00402e-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d06200c0dc2b/c9md00402e-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/5d95bf639a83/c9md00402e-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d6b325341dcb/c9md00402e-s2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/8c76db8cbe8a/c9md00402e-s3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d701975e0c7c/c9md00402e-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d754c810d018/c9md00402e-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/86d4b65ab73d/c9md00402e-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/72a6168a15dd/c9md00402e-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/b9c96f038c96/c9md00402e-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d06200c0dc2b/c9md00402e-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/5d95bf639a83/c9md00402e-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d6b325341dcb/c9md00402e-s2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/8c76db8cbe8a/c9md00402e-s3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d701975e0c7c/c9md00402e-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/d754c810d018/c9md00402e-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/86d4b65ab73d/c9md00402e-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b99/7451071/72a6168a15dd/c9md00402e-f6.jpg

相似文献

1
High affinity rigidified AT receptor ligands with indane scaffolds.具有茚满支架的高亲和力刚性化AT受体配体。
Medchemcomm. 2019 Nov 18;10(12):2146-2160. doi: 10.1039/c9md00402e. eCollection 2019 Dec 1.
2
Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.非肽类AT2受体配体的微小结构改变导致功能活性的相互转换。
ACS Med Chem Lett. 2014 Dec 8;6(2):178-82. doi: 10.1021/ml500427r. eCollection 2015 Feb 12.
3
Disila-analogues of the synthetic retinoids EC23 and TTNN: synthesis, structure and biological evaluation.合成维甲酸 EC23 和 TTNN 的二硅烷类似物:合成、结构和生物学评价。
Org Biomol Chem. 2012 Sep 14;10(34):6914-29. doi: 10.1039/c2ob25989c. Epub 2012 Jul 20.
4
Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes.
Bioorg Med Chem. 2007 Apr 1;15(7):2533-43. doi: 10.1016/j.bmc.2007.01.056. Epub 2007 Feb 2.
5
Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity.含有具有高AT2受体亲和力的1,3,5-三取代苯支架的血管紧张素II假肽。
J Med Chem. 2005 Oct 20;48(21):6620-31. doi: 10.1021/jm050280z.
6
Small-molecule AT2 receptor agonists.小分子 AT2 受体激动剂。
Med Res Rev. 2018 Mar;38(2):602-624. doi: 10.1002/med.21449. Epub 2017 Jun 13.
7
New 4-[omega-(diarylmethylamino)alkyl]- and 4-[omega-(diarylmethoxy)alkyl]-1-arylpiperazines as selective 5-HT1A/5-HT2A receptor ligands with differentiated in vivo activity.新型4-[ω-(二芳基甲基氨基)烷基]-和4-[ω-(二芳基甲氧基)烷基]-1-芳基哌嗪作为具有不同体内活性的选择性5-HT1A/5-HT2A受体配体。
Pol J Pharmacol. 2004 Nov-Dec;56(6):743-54.
8
Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides.2-氨基-9H-嘌呤-6-亚磺酰胺、-亚砜酰胺和-磺酰胺以及相关嘌呤核糖核苷的合成及其体内抗肿瘤活性
J Med Chem. 1990 Jan;33(1):121-8. doi: 10.1021/jm00163a020.
9
Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.
J Med Chem. 1993 Dec 24;36(26):4239-49. doi: 10.1021/jm00078a014.
10
Design, synthesis and biological evaluation of novel biphenylsulfonamide derivatives as selective AT receptor antagonists.新型联苯磺酰胺衍生物作为选择性AT受体拮抗剂的设计、合成及生物学评价
Front Chem. 2022 Aug 26;10:984717. doi: 10.3389/fchem.2022.984717. eCollection 2022.

引用本文的文献

1
The Angiotensin AT Receptor: From a Binding Site to a Novel Therapeutic Target.血管紧张素 AT 受体:从结合位点到新的治疗靶点。
Pharmacol Rev. 2022 Oct;74(4):1051-1135. doi: 10.1124/pharmrev.120.000281.
2
Design, synthesis and biological evaluation of novel biphenylsulfonamide derivatives as selective AT receptor antagonists.新型联苯磺酰胺衍生物作为选择性AT受体拮抗剂的设计、合成及生物学评价
Front Chem. 2022 Aug 26;10:984717. doi: 10.3389/fchem.2022.984717. eCollection 2022.
3
Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists.

本文引用的文献

1
Anti-fibrotic Potential of AT Receptor Agonists.AT受体激动剂的抗纤维化潜力
Front Pharmacol. 2017 Aug 31;8:564. doi: 10.3389/fphar.2017.00564. eCollection 2017.
2
Small-molecule AT2 receptor agonists.小分子 AT2 受体激动剂。
Med Res Rev. 2018 Mar;38(2):602-624. doi: 10.1002/med.21449. Epub 2017 Jun 13.
3
EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain.EMA401:一种曾用于血管紧张素Ⅱ2型受体(AT2R)的拮抗剂,现用于神经性疼痛的新适应症。
血管紧张素肽和肽模拟物作为血管紧张素 II 型受体(AT2 受体)激动剂的进化。
Biomolecules. 2020 Apr 23;10(4):649. doi: 10.3390/biom10040649.
J Pain Res. 2017 Feb 20;10:439-443. doi: 10.2147/JPR.S128520. eCollection 2017.
4
Angiotensin Peptides as AT2 Receptor Agonists.作为AT2受体激动剂的血管紧张素肽
Curr Protein Pept Sci. 2017;18(8):809-818. doi: 10.2174/1389203718666170203150344.
5
Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.非肽类AT2受体配体的微小结构改变导致功能活性的相互转换。
ACS Med Chem Lett. 2014 Dec 8;6(2):178-82. doi: 10.1021/ml500427r. eCollection 2015 Feb 12.
6
Saralasin and Sarile Are AT2 Receptor Agonists.沙拉新和萨立来是血管紧张素Ⅱ2型受体激动剂。
ACS Med Chem Lett. 2014 Aug 18;5(10):1129-32. doi: 10.1021/ml500278g. eCollection 2014 Oct 9.
7
Electronic sculpting of ligand-GPCR subtype selectivity: the case of angiotensin II.电子雕刻配体-GPCR 亚型选择性:血管紧张素 II 案例。
ACS Chem Biol. 2014 Jul 18;9(7):1420-5. doi: 10.1021/cb500063y. Epub 2014 May 14.
8
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.EMA401,一种口服的高选择性血管紧张素 II 型受体拮抗剂,作为治疗带状疱疹后神经痛的一种新方法:一项随机、双盲、安慰剂对照的 2 期临床试验。
Lancet. 2014 May 10;383(9929):1637-1647. doi: 10.1016/S0140-6736(13)62337-5. Epub 2014 Feb 5.
9
Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.含 1,2,4-三唑取代的 5-取代联苯-2-磺酰胺衍生物的设计、合成与生物评价作为潜在的抗高血压候选物。
Bioorg Med Chem. 2013 Dec 15;21(24):7742-51. doi: 10.1016/j.bmc.2013.10.017. Epub 2013 Oct 23.
10
Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury.MAS 癌基因和血管紧张素 II 型 2 受体激动剂可减轻新生大鼠高氧诱导肺损伤所致心肺疾病。
Am J Physiol Lung Cell Mol Physiol. 2013 Sep;305(5):L341-51. doi: 10.1152/ajplung.00360.2012. Epub 2013 Jun 28.